To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02120417
Title A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | GBR | FRA | ESP


No variant requirements are available.